标题
Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation
作者
关键词
-
出版物
Cells
Volume 8, Issue 8, Pages 854
出版商
MDPI AG
发表日期
2019-08-08
DOI
10.3390/cells8080854
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Age-related inflammation triggers skeletal stem/progenitor cell dysfunction
- (2019) Anne Marie Josephson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- L1 drives IFN in senescent cells and promotes age-associated inflammation
- (2019) Marco De Cecco et al. NATURE
- Cutting Edge: G Protein Subunit β 1 Negatively Regulates NLRP3 Inflammasome Activation
- (2019) Tomohiko Murakami et al. JOURNAL OF IMMUNOLOGY
- JAK/STAT signaling in stem cells and regeneration: from Drosophila to vertebrates
- (2019) Salvador C. Herrera et al. DEVELOPMENT
- Thromboembolic events in polycythemia vera
- (2019) Martin Griesshammer et al. ANNALS OF HEMATOLOGY
- Effect of Chronic Hematologic Malignancies on In-hospital Outcomes of Patients with ST-Segment Elevation Myocardial Infarction
- (2019) Gaurav Patel et al. AMERICAN JOURNAL OF CARDIOLOGY
- Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project
- (2018) Barbara Mora et al. HAEMATOLOGICA
- Age-related cognitive impairment is associated with long-term neuroinflammation and oxidative stress in a mouse model of episodic systemic inflammation
- (2018) Joana Costa d’Avila et al. Journal of Neuroinflammation
- Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host
- (2018) Marlies Meisel et al. NATURE
- Serum of myeloproliferative neoplasms stimulates hematopoietic stem and progenitor cells
- (2018) Richard K. Lubberich et al. PLoS One
- Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms
- (2018) Ofir Wolach et al. Science Translational Medicine
- Oncogenic JAK2 V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms
- (2018) Alessandro Prestipino et al. Science Translational Medicine
- Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms
- (2018) Valerio De Stefano et al. Blood Cancer Journal
- Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project
- (2018) Barbara Mora et al. HAEMATOLOGICA
- JAK/STAT-1 Signaling Is Required for Reserve Intestinal Stem Cell Activation during Intestinal Regeneration Following Acute Inflammation
- (2018) Camilla A. Richmond et al. Stem Cell Reports
- Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes?
- (2018) Tamas Fulop et al. Frontiers in Immunology
- Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines
- (2018) Irene Maeve Rea et al. Frontiers in Immunology
- Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations
- (2018) Stanley Chun-Wei Lee et al. CANCER CELL
- Tofacitinib for the treatment of psoriasis and psoriatic arthritis
- (2018) Anna Berekmeri et al. Expert Review of Clinical Immunology
- JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation
- (2018) Bärbel Edelmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
- (2018) Kim Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation
- (2018) Sebastien Jacquelin et al. BLOOD
- Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis
- (2018) Zhigang Cai et al. Cell Stem Cell
- Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial
- (2018) Désirée van der Heijde et al. LANCET
- Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
- (2018) Philip Mease et al. LANCET
- Classification and Personalized Prognosis in Myeloproliferative Neoplasms
- (2018) Jacob Grinfeld et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes?
- (2018) S. A. Kerrigan et al. Current Rheumatology Reports
- Tet2 restrains inflammatory gene expression in macrophages
- (2017) Alyssa H. Cull et al. EXPERIMENTAL HEMATOLOGY
- The DNA Methylcytosine Dioxygenase Tet2 Sustains Immunosuppressive Function of Tumor-Infiltrating Myeloid Cells to Promote Melanoma Progression
- (2017) Wen Pan et al. IMMUNITY
- Impact of tofacitinib treatment on human B-cells in vitro and in vivo
- (2017) Marta Rizzi et al. JOURNAL OF AUTOIMMUNITY
- Genomics of Myeloproliferative Neoplasms
- (2017) Katerina Zoi et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- JAK inhibitors in dermatology: The promise of a new drug class
- (2017) William Damsky et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
- (2017) Séverine Vermeire et al. LANCET
- Gain of function in Jak2V617F-positive T-cells
- (2017) G Nishanth et al. LEUKEMIA
- JAK2-V617F activates β1-integrin-mediated adhesion of granulocytes to vascular cell adhesion molecule 1
- (2017) N Gupta et al. LEUKEMIA
- Fibrotic progression in Polycythemia vera is associated with early concomitant driver-mutations besides JAK2
- (2017) S Bartels et al. LEUKEMIA
- The emerging safety profile of JAK inhibitors in rheumatic disease
- (2017) Kevin L. Winthrop Nature Reviews Rheumatology
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
- (2017) Andreas Hochhaus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dnmt3arestrains mast cell inflammatory responses
- (2017) Cristina Leoni et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inflammation and metabolism in tissue repair and regeneration
- (2017) Sabine A. Eming et al. SCIENCE
- Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
- (2017) Claire N Harrison et al. Lancet Haematology
- Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development
- (2017) Morten Andersen et al. PLoS One
- Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
- (2016) A Kavanaugh et al. ANNALS OF THE RHEUMATIC DISEASES
- Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study
- (2016) V.J. Ludbrook et al. BRITISH JOURNAL OF DERMATOLOGY
- The E3 Ubiquitin Ligase c-Cbl Inhibits Microglia-Mediated CNS Inflammation by Regulating PI3K/Akt/NF-κB Pathway
- (2016) Lin Dong et al. CNS Neuroscience & Therapeutics
- JAK/STAT signalling mediates cell survival in response to tissue stress
- (2016) Marco La Fortezza et al. DEVELOPMENT
- Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group
- (2016) Holly L. Geyer et al. HAEMATOLOGICA
- Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea
- (2016) Alberto Alvarez-Larrán et al. HAEMATOLOGICA
- Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
- (2016) John O. Mascarenhas et al. HAEMATOLOGICA
- Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration
- (2016) Hongwei Qin et al. JOURNAL OF NEUROSCIENCE
- A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
- (2016) S Verstovsek et al. LEUKEMIA
- Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both
- (2016) S Koschmieder et al. LEUKEMIA
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
- (2016) C N Harrison et al. LEUKEMIA
- Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms
- (2016) Luigi Gugliotta et al. LEUKEMIA RESEARCH
- Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus
- (2016) L Kahl et al. LUPUS
- Reparative inflammation takes charge of tissue regeneration
- (2016) Michael Karin et al. NATURE
- Perspective: Targeting the JAK/STAT pathway to fight age-related dysfunction
- (2016) Ming Xu et al. PHARMACOLOGICAL RESEARCH
- Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults
- (2016) Andrew L. Young et al. Nature Communications
- Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group
- (2016) Holly L. Geyer et al. HAEMATOLOGICA
- Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea
- (2016) Alberto Alvarez-Larrán et al. HAEMATOLOGICA
- Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
- (2016) John O. Mascarenhas et al. HAEMATOLOGICA
- Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- (2016) Mark C. Genovese et al. Arthritis & Rheumatology
- Defective Signaling in the JAK-STAT Pathway Tracks with Chronic Inflammation and Cardiovascular Risk in Aging Humans
- (2016) Shai S. Shen-Orr et al. Cell Systems
- Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) A. M. Vannucchi et al. ANNALS OF ONCOLOGY
- The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis
- (2015) M. Deininger et al. BLOOD
- Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
- (2015) D. P. Steensma et al. BLOOD
- JAK1/2 inhibition impairs T cell functionin vitroand in patients with myeloproliferative neoplasms
- (2015) Sowmya Parampalli Yajnanarayana et al. BRITISH JOURNAL OF HAEMATOLOGY
- JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells
- (2015) Clodagh Keohane et al. BRITISH JOURNAL OF HAEMATOLOGY
- DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype
- (2015) J. Nangalia et al. HAEMATOLOGICA
- Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function
- (2015) F Perner et al. LEUKEMIA
- The Hen or the Egg: Inflammatory Aspects of Murine MPN Models
- (2015) Jonas S. Jutzi et al. MEDIATORS OF INFLAMMATION
- A gp130–Src–YAP module links inflammation to epithelial regeneration
- (2015) Koji Taniguchi et al. NATURE
- Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6
- (2015) Qian Zhang et al. NATURE
- Type I/II cytokines, JAKs and new strategies for treating autoimmune diseases
- (2015) Daniella M. Schwartz et al. Nature Reviews Rheumatology
- Inhibition of JAK2 attenuates the increase in inflammatory markers in microglia from APP/PS1 mice
- (2015) Raasay S. Jones et al. NEUROBIOLOGY OF AGING
- Effect of Mutation Order on Myeloproliferative Neoplasms
- (2015) Christina A. Ortmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age
- (2015) Ming Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
- (2015) A Pardanani et al. Blood Cancer Journal
- JAK-STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response
- (2015) M. Kleppe et al. Cancer Discovery
- DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype
- (2015) J. Nangalia et al. HAEMATOLOGICA
- A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis
- (2015) Roy M. Fleischmann et al. Arthritis & Rheumatology
- VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis
- (2015) Mark C. Genovese et al. Arthritis & Rheumatology
- Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro
- (2014) Sheau-Pey Wang et al. ANNALS OF THE RHEUMATIC DISEASES
- Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm
- (2014) L. Lamrani et al. BLOOD
- Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
- (2014) R. Rampal et al. BLOOD
- Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
- (2014) P. Lundberg et al. BLOOD
- Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease
- (2014) S. Spoerl et al. BLOOD
- Age-Associated Loss of Lamin-B Leads to Systemic Inflammation and Gut Hyperplasia
- (2014) Haiyang Chen et al. CELL
- Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors
- (2014) S. C. Meyer et al. CLINICAL CANCER RESEARCH
- Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressingJAK2-V617F
- (2014) Pontus Lundberg et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Jak/Stat Signaling Stimulates Zebrafish Optic Nerve Regeneration and Overcomes the Inhibitory Actions of Socs3 and Sfpq
- (2014) F. Elsaeidi et al. JOURNAL OF NEUROSCIENCE
- Inhibition of JAK-STAT signaling stimulates adult satellite cell function
- (2014) Feodor D Price et al. NATURE MEDICINE
- The impact of JAK-STAT signaling on muscle regeneration
- (2014) Jason D Doles et al. NATURE MEDICINE
- Age-related mutations associated with clonal hematopoietic expansion and malignancies
- (2014) Mingchao Xie et al. NATURE MEDICINE
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- (2014) Luzhou Xing et al. NATURE MEDICINE
- Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
- (2014) Giulio Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
- (2014) Siddhartha Jaiswal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacologic Blockade of JAK1/JAK2 Reduces GvHD and Preserves the Graft-Versus-Leukemia Effect
- (2014) Jaebok Choi et al. PLoS One
- JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms
- (2014) S. Leah Etheridge et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Janus kinase inhibitors in autoimmune diseases
- (2013) John J O'Shea et al. ANNALS OF THE RHEUMATIC DISEASES
- The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
- (2013) A. Heine et al. BLOOD
- JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia
- (2013) C. M. Hobbs et al. BLOOD
- Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms
- (2013) J. Wehrle et al. HAEMATOLOGICA
- Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
- (2013) S. Verstovsek et al. HAEMATOLOGICA
- MPN patients harbor recurrent truncating mutations in transcription factor NF-E2
- (2013) Jonas S. Jutzi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib
- (2013) M Massa et al. LEUKEMIA
- Mutations and prognosis in primary myelofibrosis
- (2013) A M Vannucchi et al. LEUKEMIA
- Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor
- (2013) Srdan Verstovsek et al. LEUKEMIA RESEARCH
- No Evidence for JAK2V617F Mutation in Monoclonal B Cells in 2 Patients with Polycythaemia Vera and Concurrent Monoclonal B Cell Disorder
- (2012) C. Stijnis et al. ACTA HAEMATOLOGICA
- JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway
- (2012) M. De Grandis et al. BLOOD
- Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?
- (2012) H. C. Hasselbalch BLOOD
- Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation
- (2012) V. Rosti et al. BLOOD
- Inborn Errors of Human JAKs and STATs
- (2012) Jean-Laurent Casanova et al. IMMUNITY
- Divergent requirement for Gαs and cAMP in the differentiation and inflammatory profile of distinct mouse Th subsets
- (2012) Xiangli Li et al. JOURNAL OF CLINICAL INVESTIGATION
- Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis
- (2012) Lambert Busque et al. NATURE GENETICS
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
- (2012) Roberto Marchioli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acute Inflammation Initiates the Regenerative Response in the Adult Zebrafish Brain
- (2012) N. Kyritsis et al. SCIENCE
- TNF facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms
- (2011) A. G. Fleischman et al. BLOOD
- Endothelial progenitor cells are clonal and exhibit the JAK2V617F mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms
- (2011) L. Teofili et al. BLOOD
- Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
- (2011) Animesh Pardanani et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
- (2011) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- Clonal analysis reveals multiple functional defects of aged murine hematopoietic stem cells
- (2011) Brad Dykstra et al. JOURNAL OF EXPERIMENTAL MEDICINE
- p53 Lesions in Leukemic Transformation
- (2011) Ashot Harutyunyan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms
- (2010) F. X. Schaub et al. BLOOD
- Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells
- (2010) Ann Mullally et al. CANCER CELL
- Genetic Analysis of Transforming Events That Convert Chronic Myeloproliferative Neoplasms to Leukemias
- (2010) O. Abdel-Wahab et al. CANCER RESEARCH
- JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations
- (2010) A Pardanani et al. LEUKEMIA
- LNK mutation studies in blast-phase myeloproliferative neoplasms and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations
- (2010) A Pardanani et al. LEUKEMIA
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- c-Cbl deficiency leads to diminished lymphocyte development and functions in an age-dependent manner
- (2010) C. Rathinam et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Functionally distinct hematopoietic stem cells modulate hematopoietic lineage potential during aging by a mechanism of clonal expansion
- (2010) I. Beerman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome
- (2009) S. Sozer et al. BLOOD
- Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm
- (2009) P. A. Beer et al. BLOOD
- Cytokine/Jak/Stat Signaling Mediates Regeneration and Homeostasis in the Drosophila Midgut
- (2009) Huaqi Jiang et al. CELL
- Mutation inTET2in Myeloid Cancers
- (2009) François Delhommeau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular inflammation: Underpinnings of aging and age-related diseases
- (2008) Hae Young Chung et al. AGEING RESEARCH REVIEWS
- Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F
- (2008) F. X. Schaub et al. BLOOD
- Cytokine Signaling Modules in Inflammatory Responses
- (2008) John J. O'Shea et al. IMMUNITY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now